- Home
- MUFG vs AMGN Comparison
MUFG vs AMGN Comparison
Compare MUFG & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUFG | AMGN |
|---|---|---|
| Founded | 1880 | 1980 |
| Country | Japan | United States |
| Employees | 178953 | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 195.2B | 188.7B |
| IPO Year | N/A | 2002 |
Fundamental Metrics
Financial Performance| Metric | MUFG | AMGN |
|---|---|---|
| Price | $20.10 | $354.41 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $351.05 |
| AVG Volume (30 Days) | ★ 3.2M | 2.3M |
| Earning Date | 05-15-2026 | 04-30-2026 |
| Dividend Yield | 2.32% | ★ 2.98% |
| EPS Growth | N/A | ★ 88.23 |
| EPS | N/A | ★ 3.34 |
| Revenue | N/A | ★ $25,424,000,000.00 |
| Revenue This Year | $4.62 | $5.00 |
| Revenue Next Year | $10.12 | $2.45 |
| P/E Ratio | ★ $25.47 | $106.09 |
| Revenue Growth | N/A | ★ 8.83 |
| 52 Week Low | $13.20 | $269.77 |
| 52 Week High | $20.23 | $391.29 |
Technical Indicators
Market Signals| Indicator | MUFG | AMGN |
|---|---|---|
| Relative Strength Index (RSI) | 66.65 | 60.63 |
| Support Level | $14.80 | $334.95 |
| Resistance Level | $20.19 | $356.53 |
| Average True Range (ATR) | 0.30 | 8.10 |
| MACD | 0.03 | 2.22 |
| Stochastic Oscillator | 92.36 | 86.70 |
Price Performance
Historical ComparisonAbout MUFG Mitsubishi UFJ Financial Group Inc.
Mitsubishi UFJ Financial Group is the largest bank in Japan in terms of market capitalization and assets, with an 8.4% share of all domestic loans as of March 2025. It is the largest non-Chinese bank group globally and has a balance sheet slightly larger than those of JPMorgan Chase and HSBC Holdings. MUFG's operations in Japan account for around half of profit, banking in Thailand and Indonesia for around 15%, and equity-method earnings from Morgan Stanley most of the rest.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.